These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8256454)

  • 21. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone mineral density among postmenopausal Saudi women.
    Sadat-Ali M; Al-Habdan IM; Al-Mulhim FA; El-Hassan AY
    Saudi Med J; 2004 Nov; 25(11):1623-5. PubMed ID: 15573189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone mineral density thresholds for pharmacological intervention to prevent fractures.
    Siris ES; Chen YT; Abbott TA; Barrett-Connor E; Miller PD; Wehren LE; Berger ML
    Arch Intern Med; 2004 May; 164(10):1108-12. PubMed ID: 15159268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy.
    Sammartino A; Cirillo D; Mandato VD; Di Carlo C; Nappi C
    J Endocrinol Invest; 2005; 28(10 Suppl):80-4. PubMed ID: 16550729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
    Bunyavejchevin S; Limpaphayom KK
    J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Postmenopausal osteoporosis].
    László A
    Orv Hetil; 2004 Jan; 145(1):3-13. PubMed ID: 15222134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology, etiology, and diagnosis of osteoporosis.
    Lane NE
    Am J Obstet Gynecol; 2006 Feb; 194(2 Suppl):S3-11. PubMed ID: 16448873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoporosis: new hope for the future.
    Masi L; Bilezikian JP
    Int J Fertil Womens Med; 1997; 42(4):245-54. PubMed ID: 9309458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Estrogens, anabolic steroids and postmenopausal osteoporosis: what are the facts?].
    Birkenhäger JC
    Ned Tijdschr Geneeskd; 1991 Jun; 135(22):973-5. PubMed ID: 2062392
    [No Abstract]   [Full Text] [Related]  

  • 33. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.
    Morishige K; Yamamoto T; Sawada K; Ohmichi M; Tasaka K; Murata Y
    Arch Gynecol Obstet; 2003 Jun; 268(2):105-6. PubMed ID: 12768299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of nandrolone decanoate on bone mass in established osteoporosis.
    Passeri M; Pedrazzoni M; Pioli G; Butturini L; Ruys AH; Cortenraad MG
    Maturitas; 1993 Nov; 17(3):211-9. PubMed ID: 8133796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-blind placebo--controlled trial of nandrolone decanoate in postmenopausal osteoporosis.
    Chhaparwal M; Saraf ML
    Indian J Med Sci; 1998 Jun; 52(6):236-8. PubMed ID: 9849033
    [No Abstract]   [Full Text] [Related]  

  • 36. Nandrolone decanoate treatment of post-menopausal osteoporosis for 2 years and effects of withdrawal.
    Hassager C; Riis BJ; Pødenphant J; Christiansen C
    Maturitas; 1989 Dec; 11(4):305-17. PubMed ID: 2693918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of involutional bone loss: methodological and conceptual problems.
    Adami S; Kanis JA
    J Bone Miner Res; 1995 Apr; 10(4):511-7. PubMed ID: 7610920
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study.
    Gennari C; AgnusDei D; Gonnelli S; Nardi P
    Maturitas; 1989 Sep; 11(3):187-97. PubMed ID: 2687645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic protocols compared in the treatment of postmenopausal osteoporotic disease].
    Nardo F; Scrofani V; Costa G; Bellanca S; Petrovec MM; Clemenza F; Licciardello S
    Minerva Ginecol; 1994 Jun; 46(6):305-15. PubMed ID: 7936382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soft tissue body composition during prevention and treatment of postmenopausal osteoporosis assessed by photon absorptiometry.
    Hassager C
    Dan Med Bull; 1991 Oct; 38(5):380-9. PubMed ID: 1802623
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.